
- by sedlv
- March 15 2024
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
(March 15, 2024) | By Tyler Patchen, BioSpace.
Swedish-based gene therapy biotech Asgard Therapeutics has closed a €30 million ($32.6 million) Series A to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology, the company announced Thursday.
The funding round was led by Johnson & Johnson Innovation and RV Invest and included participation from Novo Holdings, Boehringer Ingelheim Venture Fund and Swedish VC fund Industrifonden. Johnson & Johnson Innovation and RV Invest representatives will join Asgard’s board.